UNMET THERAPEUTIC NEEDS IN PSORIATIC ARTHRITIS: DATA
FROM THE ROMANIAN REGISTRY OF RHEUMATIC DISEASES –
NEW THERAPIES AND TARGETS
CĂTĂLIN O. CODREANU 1,2, CLAUDIU C. POPESCU 1,2*, LUMINIȚA ENACHE 1,2, CORINA D. MOGOȘAN 1,2
1“Dr. Ion Stoia” Clinical Center of Rheumatic Diseases, Bucharest, Romania
2“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
*corresponding author: claudiu.popescu@reumatologiedrstoia.ro
Download Full Article

Abstract:
The objectives of this article were to identify the potential Romanian psoriatic arthritis patients (PsA) subpopulation in need
for new therapeutic principles, currently unavailable in our country. Data were retrieved electronically from the Romanian
Registry for Rheumatic Diseases (RRBR) database between January 1st and December 31st 2017. In order to define
remission and low disease activity, patients were assessed with the Disease Activity in Psoriatic Arthritis (DAPSA) and
Simplified Disease Activity Index scores. Of the 804 PsA patients enrolled in RRBR in 2017, 721 (89.7%) patients were
treated with biologics for more than 6 months. Of these, 86 patients (11.9%) were in moderate and high disease activity
according to DAPSA and 196 patients (27.2%) according to SDAI, respectively. Compared to patients in DAPSA remission
or low disease activity, these patients had a higher toll of inflammation and a higher prevalence of sacroiliitis. Up to 30% of
Romanian PsA patients registered in RRBR would be candidates for new and locally unavailable biologic and synthetic
disease-modifying anti-rheumatic drugs, such as abatacept, apremilast, certolizumab, ixekizumab, tofacitinib and
ustekinumab.

Top